TAMPA, FL – 11-01-2017 (Press Release Jet) —
The Ultroid Group notifies, simultaneously with this announcement that all affiliates, business partners, contractors, etc. and their respective assigns are that Dragon Jade and it representative have no authority to negotiate, contract for, receive information concerning or otherwise bind The Ultroid Group in anyway and that any such authority that may have been given expressly or implied is hereby terminated. Please contact us directly with any questions or concerns.
Ultroid Technologies, Inc. manufactures and markets the Ultroid® Hemorrhoid Management System (“Ultroid® System”). The Ultroid® System, which is FDA cleared and also approved for use in many other nations, is a non-surgical, non-anesthetic, and rapid treatment for hemorrhoid disease (HD).
The Ultroid® System is covered by most major insurers and Medicare, and has been successfully utilized in an estimated 180,000 procedures, by several hundred physicians, practices, clinics, and surgical centers. The Ultroid® procedure is currently offered in over 150 clinics in the US and was introduced in UK in 2013 where it is currently offered in 15 clinics.
ULTROID MARKETING DEVELOPMENT CORP.
Michael J. Goeree, Chairman, CEO & President
Michael A. Knox, CPA, Director, Exec. VP & CFO
2919 W. Swann Avenue
Suite 106 A
Tampa, FL 33609
For the original news story, please visit https://pressreleasejet.com/news/termination-of-option-to-purchase-agreement-and-refutal-of-october-3rd-mou-signing.html.
Powered by WPeMatico